92 results on '"Lopez-Vivanco, Guillermo"'
Search Results
2. Nurse-Supervised Exercise for People with Stage IV Cancer: The EFICANCER Randomized Clinical Trial
3. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
4. First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met
5. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
6. A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis
7. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
8. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
9. Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non–small cell lung cancer.
10. Phase I/II and Pharmacokinetic Study of Intravenous Vinflunine in Combination With Cisplatin for the Treatment of Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer
11. Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients
12. Abstract 560: High levels of baseline ctDNA constitute a poor prognostic factor in progression-free survival in patients receiving neo-adjuvant chemo-immunotherapy: Results from NADIM clinical trial
13. Screening for epidermal growth factor receptor mutations in lung cancer
14. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients (p): SOLID study.
15. Hereditary pancreatic cancer: related syndromes and clinical perspective
16. Factores pronósticos en metástasis pulmonares resecables de carcinoma colorrectal
17. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer
18. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: BIBABRAX study.
19. Malignant Mesothelioma
20. Factores pronósticos y predictivos en pacientes con cáncer de origen desconocido tratados con un esquema de quimioterapia con paclitaxel
21. Chemotherapy for Bladder Cancer
22. Neutropenic fever: Incidence in 1 year and outcome. Validation of MASCC (Multinational Association for Supportive Care in Cancer) risk-index score
23. A novel schedule with biweekly cisplatin (C) and gemcitabine (G) in advanced non-small cell lung cancer (NSCLC)
24. Mytomicin, ifosfamide and cisplatin versus cisplatin and gemcitabine in patients with advanced non-small cell lung cancer (NSCLC): a single institution retrospective analysis of 363 patients
25. Value of systemic postoperative chemotherapy in resected colo-rectal liver metastasis
26. Haematological biomarkers of pathological response on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA non-small cell lung cancer (NSCLC) patients.
27. Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.
28. Long-term responders to first-line bevacizumab-based therapy in metastatic breast cancer (MBC) patients: Results of the observational study LORENA.
29. Aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Safety and quality of life (QoL) data from the Spanish subgroup of the Aflibercept Safety and Quality-of-Life Program (ASQoP).
30. Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile
31. Association of PALB2Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer
32. Final results of a phase II study of bevacizumab, cisplatin and pemetrexed as first-line therapy for patients with advanced non squamous non small cell lung cancer.
33. BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p).
34. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can
35. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC)
36. Supervised physical exercise to improve the quality of life of cancer patients: the EFICANCER randomised controlled trial
37. P3.02b-047 Co-Activation of STAT3 and YAP1 Signaling Pathways Limits EGFR Inhibitor Response in Lung Cancer: Topic: EGFR Clinical
38. P2.06-010 AZD9291 as 1st-Line Therapy for EGFR Mutant NSCLC Patients with Concomitant Pretreatment EGFR T790M Mutation. The AZENT Study: Topic: Phase II + NK
39. Extravasation of docetaxel: a red hand syndrome
40. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine
41. Preoperative chemoradiotherapy (QT-RT) with capecitabine and oxaliplatin (CAPOX) or capecitabine alone (CAP) in patients (PTS) with locally advanced rectal cancer (LARC).
42. Bevacizumab (BV) plus irinotecan (I) in recurrent glioblastoma multiforme (GBM): A single center experience.
43. Preoperative chemoradiotherapy (QT-RT) with capecitabine and oxaliplatin (CAPOX) in patients with locally advanced rectal cancer.
44. Elderly patients and ovarian epithelial cancer (OEC) or primary peritoneal carcinoma (PPC): A retrospective analysis.
45. Tolerability of raltitrexed when it is used in monotherapy and in combination with oxaliplatin (TOMOX) as advanced colorectal cancer treatment in normal clinical practice.
46. Long-term responders to first-line bevacizumab-based therapy among patients (pts) with HER2-negative metastatic breast cancer (MBC): Retrospective results of an ambispective observational study.
47. Adjuvant chemotherapy with cisplatin and gemcitabine in resected non-small cell lung cancer: A single institutional experience.
48. Bevacizumab plus chemotherapy in the treatment of metastatic breast cancer: Hospital of Cruces experience.
49. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)—Final results.
50. Bevacizumab (B), cisplatin (C), and pemetrexed (P) plus maintenance B in chemonaive patients (pts) with advanced nonsquamous non-small cell lung cancer (nsNSCLC): A phase II study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.